Objectives: Recent increases in triazole resistance in Aspergillus fumigatus have been attributed primarily to target site (cyp51A) mutations. A recent survey of resistant isolates in Manchester showed that .50% of resistant isolates had no mutation in cyp51A or its promoter. We investigated the mechanisms of resistance in clinical azole-resistant isolates without cyp51A mutations.
Introduction
Fungal disease affects individuals with dysfunctional immune responses. The most commonly affected are those with hyperactive immune responses, such as atopic individuals, who may have complications of asthma caused by fungal allergy. 1, 2 Immunocompromised individuals are subject to devastating, frequently fatal invasive mycoses. 3 Finally, ostensibly normal individuals can occasionally suffer from cavitating forms of fungal disease. 4 The two most important genera affecting human health are Candida and Aspergillus, with Aspergillus fumigatus being the most common cause of mould-related mycosis. 5 Therapy for fungal disease is limited to a small number of drug classes, including azoles, echinocandins and polyenes. Azoles are the most commonly used antifungal therapy and resistance to azoles has been observed in Candida and more recently Aspergillus. The mortality of patients with multi-azoleresistant invasive aspergillosis was 88% compared with 30% -50% who were infected with azole-susceptible strains. 6 Time from diagnosis to resolution of the infection or death in invasive forms of fungal disease is typically a few weeks, whereas in allergic or chronic diseases patients may take antifungal medication for many years. In both cases drug resistance is highly problematic. Only azoles are orally active against Aspergillus, restricting patients who harbour drug-resistant isolates to intravenous treatment options.
Azoles act by inhibiting the activity of the cytochrome p450 gene lanosterol 14-a-demethylase, a key enzyme in biosynthesis of ergosterol. It is thought that lack of ergosterol diminishes membrane rigidity and leads to fungal cell death. 7 Azole resistance in Candida albicans and Candida glabrata and other yeasts is well studied 8 -19 and the majority of cases are thought to be attributable to overexpression of the drug efflux transporters CDR1, CDR2 and MDR1 or to mutations in the transcription factors TAC1 and MRR1 that lead to overexpression of the transporter genes. 14 -16 Mutations at the azole target gene cyp51A are also frequently observed. 20, 21 Alternatively, aneuploidy arising from duplications in chromosomal regions containing these genes or their orthologues has also been observed to lead to azole resistance in both Candida spp. and Cryptococcus neoformans. 22, 23 Itraconazole resistance was first reported in A. fumigatus in 1997 (in isolates obtained from the USA in the late 1980s). 24 Since then, many reports have described resistance in A. fumigatus clinical isolates in Belgium, Canada, China, Denmark, France, Norway, Spain, Sweden, the Netherlands, the UK, the USA 25 -28 and recently India. 29 The global frequency is not clearly defined as many laboratories do not test the azole susceptibility of clinical A. fumigatus isolates or use a common standard method for susceptibility. A dominant target mutation (TR+ L98H) appears to be common in the environment in the Netherlands and China. 28, 30 In a recent survey of azole-resistant A. fumigatus in a UK referral clinic a striking rise in drug resistance was observed. 6, 26, 31 Until 2008 all observed resistance was attributable to mutations in the cyp51A gene; however, between 2008 and 2010 resistant isolates containing no mutations in this gene or promoter became more prevalent. In 2010, 51% of Manchester isolates that were resistant to azoles were non-cyp51A. This is a major concern as molecular assays developed to provide rapid diagnosis of cyp51A-based drug resistance are of no utility in this set of isolates.
Although several studies have demonstrated an increase in transcription of transporter genes in azole-susceptible isolates, previous attempts to define whether A. fumigatus can become clinically drug resistant in the same transporter expressiondependent manner as C. albicans have been inconclusive. Two major facilitator transporters, AfuMDR1 and AfuMDR2, were identified by Tobin et al. 32 Slaven et al. 33 observed overexpression of atrF in a clinical azole-resistant isolate, AF72. Nascimento et al. 34 showed up-regulation of two transporters, AfuMDR3 and AfuMDR4, in 2/23 laboratory mutants that were resistant to itraconazole, the latter of which has also been shown to be up-regulated in a biofilm phenotype. 35 da Silva Ferreira et al. 36 showed induction of five ABC transporters, abcA -E, and MFS transporters mfsA -C in response to voriconazole in a laboratory-derived clinical azole-susceptible isolate, CEA17. However, the relationship of these findings to clinical azole resistance has not been convincingly demonstrated.
Here we used the results from these previous studies, together with genes predicted by comparison with C. albicans drug resistance genes, to attempt to discover drug efflux transporters that are clinically important in the development or maintenance of azole resistance in A. fumigatus. Our rationale was to survey existing knowledge of azole transporters in A. fumigatus, then to test the function of candidate genes in clinical isolates of A. fumigatus that were resistant to azoles but that did not carry a cyp51A mutation, in order to avoid unnecessary complexity and to characterize the mechanism of resistance in the increasingly common non-cyp51A isolates.
Materials and methods

Strains and media
A. fumigatus clinical isolates, obtained from the Mycology Reference Centre Manchester (MRCM), UK were used throughout this work (Table 1) . Itraconazole-resistant isolates were selected from a total of 230 A. fumigatus clinical isolates received between 1 January 2008 and 31 December 2009. 6, 26 The MICs for the isolates were determined using the broth microdilution method as previously described. 37 An A1160 DKu80 pyrG + strain (here referred to as A1160 pyrG + ) was constructed in this study and served as a parental strain for transporter gene deletion mutants. A. fumigatus isolates and strains were typically stored as stock spore suspensions in sterile glycerol nutrient broth at 2808C and subsequently subcultured on Sabouraud dextrose agar (SDA) (Oxoid) for transformation or Vogel's minimal agar 38 containing 1% glucose for MIC determination and incubated at 378C for 24 h before spores were used. Spores were harvested in 1× PBS with 0.05% Tween 20, counted using an Improved Neubauer haemocytometer (Weber Scientific International, Cambridge, UK) and adjusted to 1×10 5 cfu/mL for MIC determination or to 1×10 6 cfu/mL for transformation, DNA or RNA cultivation. For transformation a YPS medium was used, composed of 2% yeast extract (Oxoid), 0.5% peptone (Oxoid), 0.9 M sucrose (Sigma), 5 mM Tris base (Sigma) and 1.5% technical agar (Oxoid) (pH 6 for transformation of hygromycin cassettes and pH 8 for transformation of phleomycin cassettes).
Quantification of gene expression by RT-PCR
RT-PCR was performed on an Mx3005p real-time PCR machine (Stratagene) essentially as previously described. 39 Negative controls consisted of no-RNA or no-template wells with or without reverse transcriptase. Primers were optimized and tested individually to minimize primerdimer artefacts. After the RT-PCR, melting curve determination was performed and 5 mL of each sample was analysed by gel electrophoresis on a 1% agarose gel to ensure that there was no non-target amplification. The RT-PCR was typically performed in 25 mL reactions containing 50 ng of A. fumigatus RNA, 2 pmol of each forward and reverse primer and 12.5 mL of Brilliant SYBR Green qRT-PCR Mix (Stratagene). PCR was carried out under the following conditions: 508C for 60 min (for reverse transcription) then 958C for 10 min followed by 40 cycles of 958C for 30 s, 608C for 1 min and extension at 728C for 1 min. Results were analysed using the 2 2DDCt method. Primers used are shown in Table S1 (available as Supplementary data at JAC Online). Statistical analysis followed the method suggested by Yuan et al., 40 essentially using two group t-tests and non-parametric analogous Wilcoxon tests on paired samples, usually delta Ct values from the same gene in different isolates ranked against the same gene in Af293, using SPSS.
Construction of the A1160 DKu80 pyrG 1 strain
An A1160 DKu80 pyrG + strain was constructed as a parental strain for transporter gene deletion mutants. The CEA17DakuB ku80 pyrG 2 strain (FGSC A1160), 33 containing a single base-pair mutation in pyrG, 40 was transformed with a functional A. fumigatus pyrG gene derived from A1163 by PCR using primers Afpyrg-F and Afpyrg-R (Table S1) 
Construction of transporter gene deletion cassettes
Gene knockout cassettes were constructed by a modified PCR fusion method. 41, 42 Four sets of primers were used in order to create each deletion cassette (Table S1 ) for AFUA_1G14330 (cdr1B) and AFUA_1G05010 (MFS56). Primer sets P1-P2 and P5-P6 were used to amplify the upstream and downstream flanking regions of the genes, respectively. Primers P3-P4 amplified a 2.8 kb hygromycin B phosphotransferase cassette from pAN7-1 including the gpdA promoter and TtrpC terminator (hph cassette). 43 The above primers were used in three separate PCRs (first-round PCR) consisting of 100 ng of Af293 genomic DNA or 10 ng of plasmid DNA, 0.2 mM of forward and reverse primers, 200 mM dNTPs, 2 U of the LongAmp Taq DNA polymerase (NEB) and 1× reaction buffer in a total volume of 25 mL. Cycling conditions were: 1 cycle at 948C for 30 s, then 35 cycles at 948C for 15 s, 558C for 15 s and 688C for 3 min. A single elongation step at 688C for 5 min was performed at the end of the reaction. Upstream and downstream flanking regions of the genes were column purified using a Qiagen PCR purification kit. The hygromycin cassette was gel purified using a Qiagen gel purification kit.
Primers P7 and P8 (nested) were used in the second-round PCR to fuse the three first-round PCR fragments. The reaction mixture was composed of 1 mL of gel-purified first-round PCR products ( 100 ng each), 0.4 mM of forward and reverse primers, 400 mM of dNTPs, 4 U of the LongAmp Taq DNA polymerase and 1× reaction buffer in a total volume of 50 mL. The reaction was run at 558C annealing and 5 min elongation as in Weidner et al. 44 Direct PCR products of both Dcdr1B::hph and DMFS56::hph were used to delete transporter genes in A1160 DKu80 pyrG + and F20063 clinical isolates. For double cdr1B and MFS56 knockout, a 2.15 kb phleomycin cassette from pAN8-1 under the gpdA promoter and TtrpC terminator 45 was constructed with the same primers, P1-P8, as for the hph cassette because they share the same amplification regions in the gpdA promoter and TtrpC terminator. This cassette was used for transformation of A1160 DKu80 pyrG + DMFS56::hph, generating a A1160 DKu80 pyrG + Dcdr1B::phleoDMFS56::hph mutant (A1160 pyrG + Dcdr1BDMFS56).
Fungal transformation
Fungal transformations were performed using an optimized Ballance and Turner method. 46 Briefly, spores (2×10 6 /mL) were grown in 50 mL of liquid SDA broth containing 100 mg/mL ampicillin distributed into three 9 cm Petri dishes for 14 -16 h at 378C (static culture). The hyphae were harvested by filtration through a single layer of lens tissue, washed once in 1× PBS, then digested in 20 mL of sterile 50 mM CaCl 2 /0.6 M KCl solution (pH 7.6) containing 1 g of Glucanex 200G (Novozyme) at 308C for 3 h with gentle mixing (100 rpm) to form protoplasts. The digestion mixture was filtered through two layers of lens tissue and the protoplasts were centrifuged at 800 g for 5 min at 48C. The pellet was resuspended in 1 mL of cold 50 mM CaCl 2 /0.6 M KCl solution and protoplasts were counted using an Improved Neubauer haemocytometer, then adjusted to give 1×10 6 per 100 mL aliquot. Fifteen microlitres of the second-round PCR product was added to each aliquot and mixed with 20 mL of 40% polyethylene glycol (PEG) 6000 (prepared in 50 mM CaCl 2 /0.6 M KCl) followed by incubation on ice for 25 min. Subsequently, 200 mL of 40% PEG6000 was added and the protoplasts were incubated for 5 min at room temperature. The mixtures were transferred onto solid YPS medium supplemented with 200 mg/mL hygromycin B and/or 150 mg/mL zeocin (Melford) and incubated at 378C until the appearance of resistant colonies. These were streaked on SDA supplemented with 200 mg/mL hygromycin B and/or 150 mg/mL zeocin (Melford) and a single colony from each strain was grown on the same medium for DNA extraction and other subsequent analyses (below).
DNA extraction
DNA extractions were performed on spores using an optimized cetyl trimethyl ammonium bromide (CTAB) DNA extraction method. Briefly, spores were harvested in PBS/Tween 20, centrifuged at 6000 g for 2 min and resuspended in 1 mL of extraction buffer (2% CTAB, 100 mM Tris, 1.4 M NaCl and 10 mM EDTA, pH 8.0) and transferred to a 2 mL screw-top tube containing 425-600 mm washed glass beads (filled to the 300 mL mark; 50 mg) (Sigma). Subsequently they were vortexed for 10 min at maximum speed (Genie-2) and incubated for 10 min at 658C. Vortexing and heating steps were repeated. The spores were centrifuged at maximum speed for 2 min and the supernatant was transferred to a 2 mL tube containing 4 mL of 100 mg/mL RNase (Qiagen) and incubated at 378C for 15 min. Then 700 mL of chloroform:isoamyl alcohol (24 :1) was added, the tube was mixed and centrifuged at maximum speed for 2 min. The aqueous phase was transferred to a 1.5 mL Eppendorf tube and 0.6 volumes of isopropanol was added. The tube was mixed and centrifuged as above. Isopropanol was decanted and the pellet was washed in 500 mL of 70% ethanol and centrifuged for 1 min at 8000 g. The alcohol was decanted and the tube was pulsecentrifuged. The residual alcohol was removed using a gel-loading tip and the pellet was resuspended in 100 mL of H 2 O. This protocol provided large amounts of good-quality genomic DNA.
Analysis of mutants
The pyrG locus of the A1160 DKu80 pyrG + strain was sequenced with primers PyrGMutsq-F and PyrGMutsq-R to confirm the pyrG 2 gene replacement. Primers PyrGck-F and PyrGck-R were used to confirm correct integration. All transporter gene deletion mutants were screened by PCR with two sets of primers: P1-P4 and P5-P6, which only generated PCR products if correct integration events occurred. Additionally, primers P9 and P10 were used to confirm gene deletion. These primers match the sequence of the target gene. The A1160 DKu80 pyrG + and F20063 DNAs were used as the template for positive PCR control reactions.
RNA extraction
Six baffled conical flasks containing 40 mL of Vogel's medium with 1% glucose were inoculated with spores to a final concentration of 1×10 6 spores/mL then incubated at 378C with shaking at 250 rpm for 14-16 h. Itraconazole was added to one set of three flasks to a final concentration of 4 mg/L for .8 mg/L resistant isolates. An equivalent volume of DMSO was added to the other set of three control flasks. Subsequently, fungal mycelia were collected by centrifugation at 3000 g, then 100 mg of fungal mycelium was transferred to a red-cap tube containing 1 mL of RNApro TM Solution (Lysing Matrix). RNA was extracted using a FastRNA w Pro Red kit (Qbiogene) according to the manufacturer's instructions. RNA was measured spectrophotometrically then diluted to 25 ng/mL. Aliquots of RNA were stored immediately at 2808C until use.
Results
Selection and characterization of non-cyp51A-resistant isolates
Susceptibilities to the antifungals itraconazole, posaconazole and voriconazole were determined for 64 azole-resistant clinical isolates provided by the MRCM during 2008-09 as previously described. 6, 26 Candida krusei ATCC 6258 was used as a control strain for each MIC plate. All control results (data not shown) were within the acceptable target range. MIC values for resistant A. fumigatus isolates were consistent with clinical laboratory Non-cyp51A-mediated azole resistance results obtained at the time of isolation. The entire cyp51A gene and 1 kb promoter was sequenced in each isolate. Briefly, isolates were subjected to PCR to amplify overlapping regions of the cyp51A gene using primer pairs cyp51_6-F and cyp51_8-R, cyp51_4-F and cyp51_2-R, cyp51_1-F and cyp51_7-R and cyp51_3-F and cyp51_5-R (Table S1 ), amplicons were sequenced in both directions and the resulting assembled sequence was examined to determine the presence of non-synonymous singlenucleotide polymorphisms (SNPs) or other mutations. Strains that did not carry mutations or that carried mutations not thought to be associated with azole resistance were selected for further analysis (Table 1) . One strain, F17999, carrying cyp51A mutation G448S, known to be associated with resistance to voriconazole and posaconazole, 6 was also included for comparison. There is no correlation between azole treatment and resistance in either duration or azole type. For example isolate F19980 was isolated from an individual with a history of posaconazole treatment yet the isolate is resistant to voriconazole and itraconazole, but not posaconazole (Table 1) . Strain F17727 was isolated from an individual with a history of itraconazole and voriconazole treatment yet is resistant to itraconazole, voriconazole and posaconazole. Alternatively, F18454 is derived from an individual with a short period of voriconazole treatment and shows only voriconazole resistance. The underlying disease, type of fungal disease, age or sex also appear not to correlate with resistance. These observations must be treated with some caution. It is possible that individuals had been treated with widely available fungicides such as itraconazole without the treatment being recorded; however, the restricted use of voriconazole and posaconazole would indicate that records of usage are more accurate.
Bioinformatic analysis of potential A. fumigatus azole transporter genes
In order to determine whether the A. fumigatus genome carried the same complement of drug-resistance genes previously identified in C. albicans and to clarify the diverse historical descriptions of A. fumigatus transporters associated with drug resistance for further study, an analysis of orthology was carried out by the Best-Reciprocal-Hits from BLAST method. Essentially, C. albicans gene sequences (CDR1, CDR2, MDR1, TAC1 and MRR1) were compared with the A. fumigatus genome (Af293) using BLASTX, TBLASTN and BLASTN using an 1E 220 cut-off. AfuMDR1-2, AfuMDR3-4, abcA-E, mfsA-C, ABC11, MFS56 [50] and atrF were compared with the C. albicans genome (SC5314 build 19) in a similar manner. Resulting BLAST hits in the A. fumigatus genome were then compared back with C. albicans and hits in the A. fumigatus genome were compared back with the C. albicans genome using a cut-off score of 1E 220 to assess orthology (Table S2 , available as Supplementary data at JAC Online).
CDR1 and CDR2 show homology (45%-50% identity) to the same set of A. fumigatus genes annotated as ABC transporters. However, when these A. fumigatus genes were compared with the C. albicans genome they revealed homology to CDR1 and CDR4, suggesting that there is no true orthologue of CDR2 in A. fumigatus. In this case AFUA_2G15130 and AFUA_1G14330 would be paralogous to each other and orthologous to CDR1. For clarity we term these genes cdr1A (AFUA_2G15130, previously annotated as CDR4) and cdr1B (AFUA_1G14330), previously referred to as abcC and ABC11, 36, 47 throughout. CaMDR1 had weak homology (30%-34% identity) to a group of A. fumigatus genes annotated as MFS transporters that in turn showed homology to the C. albicans gene MDR1. The C. albicans genes TAC1 and MRR1 and the A. fumigatus genes abcB, AfuMDR3, mfsA and mfsC appear to possess no true orthologues in the C. albicans genome. The A. fumigatus abcA gene 34 is the same as AfuMDR1 32 and, with abcA, abcD, abcE and AfuMDR2, AfuMDR4 appears to be orthologous to a group of C. albicans mitochondrial ABC transporters containing MDL1, MDL2 and HST6. A. fumigatus mfsB shows orthology to C. albicans DHA1. The lack of orthology in these groups reflects the fact that the different organisms may possess different complements of transporters. Orthology of suspected drug transporters to proteins annotated as glycerol or peptide transporters may reflect 'rewiring' of transporter function or simply incorrect annotation. From 11 A. fumigatus transporter genes previously implicated in azole resistance, only abcC (ABC11), abcB and mfsB are orthologous to known Candida efflux genes.
Analysis of basal and azole-induced transporter gene transcription in resistant and susceptible A. fumigatus isolates
To determine whether the non-target resistance observed in the Manchester strains could be explained by an increase in transporter expression in a manner analogous to known C. albicans drug resistance mechanisms, RT-PCR was used to analyse a set of 20 transporter genes as well as cyp51A in minimal medium with and without sub-MIC levels (1 mg/L itraconazole in Vogel's glucose) of itraconazole. The set of transporters was chosen on the basis of homology to known C. albicans azole resistance genes, CDR1 and MDR1 (AFUA_2G15130, AFUA_ 1G14330, AFUA_1G17440, AFUA_5G00790, AFUA_3G07300, AFUA_2G11580, AFUA_2G16860, AFUA_1G06440 and AFUA_ 1G10370; Table S2 ), known for induction in response to azole in wild-type (azole-susceptible) Af293, consisting of abcA -E and mfsA-C, 33 MDR1, MDR2, AfuMDR3, AfuMDR4 34 and atrF, 33 and for probable involvement in azole resistance from a previous insertional mutagenesis screen in our laboratory (CDR1-B¼ abcC: AFUA_1G14330, MFS56: AFUA_1G05010). 47 Expression levels for the 20 transporter genes and cyp51A were determined by RT-PCR using b-tubulin expression as a comparator. Both basal levels ( Figure 1 ) and fold induction compared with basal level after addition of azole ( Figure 2) were determined in the azolesusceptible strain Af293. Two other azole-susceptible controls, Af210 and CEA10, were also analysed (not shown), but showed ,10% variation in expression for the genes tested when compared with Af293. Most genes were poorly expressed during normal growth, with expression levels typically ,20% of the b-tubulin comparator (Figure 1 ). Expression was not detectable for AfuMDR3. Fourteen of the genes were induced .2-fold upon exposure to azole, 10 of which were induced 4-5-fold by azole (Figure 2 ). The C. albicans MDR1 orthologue AFUA_ 2G11580 was induced 14.2-fold on azole exposure, although this is compared with a very low basal expression. The cdr1A orthologue was induced 6.4-fold in response to azole treatment and the CDR4 orthologue AFUA_1G17440 was induced 7.1-fold. Basal cyp51A expression in Af293 was 0.13-fold that of b-tubulin and was induced 5.3-fold in the presence of azoles.
Fraczek et al. abcB AFUA_1G10390 abcC AFUA_1G14330 abcD AFUA_6G03470 abcE AFUA_7G00480 AfuMDR1 AFUA_5G06070 AfuMDR2 AFUA_4G10000 AfuMDR3 AFUA_3G03500 AfuMDR4 AFUA_1G12690 mfsA AFUA_8G05710 mfsC AFUA_1G03200 AFUA_1G17440 AFUA_5G00790 AFUA_3G07300 AFUA_5G02260 atrD AFUA_4G08800 CDR1 AFUA_2G15130 Mdr1 AFUA_2G11580 MFS56 AFUA_1G05010 tub mfsB AFUA_1G15490 Figure 1 . Basal levels of transporter expression in Af293. RNA was extracted from mycelia growing without addition of azole. RT-PCR was used to quantify expression for each gene shown as previously described. Three biological replicates were performed with three technical replicates from each sample. Mean values shown are relative to b-tubulin (tub). AbcC¼cdr1B. Error bars represent standard deviations. Gene names and orthology can be found in Table S2 . Gene names and orthology can be found in Table S2 .
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Over-induction of efflux transporters in clinical azole-resistant isolates
We reasoned that efflux transporters important in azole resistance would be more strongly up-regulated in clinical azole-resistant isolates compared with susceptible isolates and performed expression analysis on the clinical azole-resistant isolates in our collection using azole-susceptible isolates as controls. Several transporters (abcA, abcB, abcD, abcE, mfsA-C and cdr1A) showed non-significant differences in induction between any azole-resistant mutant and azole-susceptible comparator strain Af293 and are not shown in Figures 3 and 4 for clarity. AfuMDR3 and AfuMDR4 showed a small reduction in both basal expression and induction. Eight of 10 non-cyp51A azole-resistant strains showed significantly higher basal levels of expression of cdr1B compared with Af293; in particular F20140, F18304 and F18454 showed .25-fold greater basal expression levels than Af293. F19980 (7.2-fold), F20063 (6.5-fold), F20451 (3.6-fold), F18454 (5.1-fold) and F15483 (2.1-fold) also showed significantly raised levels of basal expression in comparison with Af293 (Figure 3) .
Ten of 12 azole-resistant isolates showed significantly higher levels of induction of MFS56 than Af293 ( Figure 4) ; notably F20063, F18085 and F17999 showed .300-fold overexpression of MFS56 compared with Af293. Several other isolates also exhibited high overexpression of MFS56 (F19980, 27.8-fold; F20140, 35.6-fold; and F20451, 17.7-fold). F17999 also showed increased induction of atrF (31.7-fold). One strain, F18085, showed overexpression of AfuMDR1 (36.5-fold) and two others, F18304 and F19980, showed high-level induction of cyp51A (550.9-and 21-fold, respectively).
Test of gene function in azole-susceptible strain by gene knockout
In order to confirm whether the overexpressed transporters AfuMDR1-4, cdr1B, MFS56 and atrF played a functional role in Table 1 for details). Error bars represent standard deviations. CYP51A, cyp51A (AFUA_4G06890); AfuMDR1, AFUA_5G06070; AfuMDR2, AFUA_4G10000; AfuMDR3, AFUA_3G03500; AfuMDR4, AFUA_1G12690; AtrF; CDR1B, AFUA_1G14330; MFS56, AFUA_1G05010.
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azole resistance, these genes were knocked out in A1160 DKu80 pyrG + . These genes were selected on the basis of their induction by azole in either azole-susceptible or azole-resistant isolates or as controls suspected to play no role in resistance (AfuMDR2, AfuMDR3 and AfuMDR4).
Genes were knocked out and verified using PCR. In order to exclude random mutational effects from transformation, two individual knockout transformants were selected for each gene knockout. After analysis and two rounds of single-spore plating, knockouts were tested for MICs of itraconazole in triplicate (Table 2) . Most knockouts had MICs that were identical to those for the wild-type. However, the cdr1B knockouts reproducibly showed an MIC of itraconazole, voriconazole and posaconazole 4-fold lower than that for the parental strain. The AfuMDR1 knockout reproducibly showed an MIC of itraconazole, voriconazole and posaconazole 2-fold lower. The double knockout A1160 pyrG + Dcdr1BDMFS56 strain showed the same MIC change as the single A1160 pyrG + Dcdr1B mutant.
In order to directly test transporter function in the azole-resistant clinical isolates, the MFS56 and cdr1B genes were knocked out in F20063, which showed a 6.3-fold induction of cdr1B and .300-fold induction of MFS56. Attempts to transform the other high-level-expression clinical isolates were unsuccessful. For F20063, the MICs of itraconazole, voriconazole and posaconazole were .8, 1 and 0.5 mg/L, respectively (Tables 1 and 2 ). MICs of voriconazole and itraconazole were determined for parental and three independent knockout strains for the cdr1B knockout (F20063Dcdr1B) and four independent knockout strains for the MFS56 knockout (F20063DMFS56) ( Table 2) . For all knockouts the MICs of voriconazole and posaconazole were unchanged.
F20063Dcdr1B-5, F20063Dcdr1B-6 and F20063Dcdr1B-7 showed MICs of itraconazole of 2 mg/L (4-fold lower than F20063), whereas F20063DMFS56-2, F20063DMFS56-4, F20063DMFS56-6 and F20063DMFS56-7 had unchanged MICs of itraconazole of .8 mg/L. Table 1 for details). CYP51A, cyp51A (AFUA_4G06890); AfuMDR1, AFUA_5G06070; AfuMDR2, AFUA_4G10000; AfuMDR3, AFUA_3G03500; AfuMDR4, AFUA_1G12690; AtrF; CDR1B, AFUA_1G14330; MFS56, AFUA_1G05010.
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Discussion
Here we attempted to identify efflux transporters associated with clinical azole resistance in A. fumigatus. A small bioinformatic meta-analysis was performed to identify potential transporter genes of interest and to clarify existing nomenclature. Nineteen A. fumigatus transporter genes were defined through bioinformatic analysis and a further two genes were added from a previous insertional mutagenesis screen. 45 One of these genes, ABC11 (cdr1B), was identical to abcC, giving a total of 20 genes of interest. Fourteen of these genes, including the C. albicans CDR1 orthologue cdr1A, were .2-fold up-regulated in the azole-susceptible clinical isolate Af293 (Figure 2 ), but were not induced in a different manner in clinical azole-resistant strains. Since Af293 remains azole susceptible, this strongly suggests that these genes are not involved in azole resistance.
It was surprising that none of the transporters that are up-regulated in response to azole in azole-susceptible isolates differ significantly (.2-fold) in their induction by azole in the non-cyp51A-resistant isolates. This result appears counterintuitive; however, the observed up-regulation does not confer resistance on the drug-susceptible strains and may possibly reflect secondary effects of azole on metabolism. Large increases in basal level of cdr1B and induction of MFS56 were associated with resistance. MFS56 is a major facilitator family transporter not previously reported to be involved in azole efflux in any organism. A. fumigatus cdr1B (abcC) is an orthologue of CDR1, although it has not previously been defined as such as A. fumigatus carries a paralogue of this gene (cdr1A, AFUA_1G17440) that is slightly more closely related to CDR1. This gene is not over-induced in resistant isolates. Eight of 11 azole-resistant isolates in this study displayed basal levels of cdr1B .5-fold greater than that observed in susceptible isolates, together with high induction of MFS56 expression (F20063, F18085 and F17999). F18304 also showed high-level induction of cyp51A. This strain is resistant to itraconazole, but susceptible to other azoles. This suggests that models of multi-azole resistance based solely on cyp51A mutation or expression may be incomplete. The findings do not explain the variable levels of resistance to other azole drugs and therefore other factors are likely to be involved in these cases. One isolate, F18329, that displayed intermediate voriconazole resistance, but normal itraconazole and posaconazole susceptibility, did not display any major change in expression of MFS56 or cdr1B when exposed to azole. However, AfuMDR1 basal levels were 3.3 times that observed in azole-susceptible strains and this may account for the slightly elevated MIC of voriconazole. F18085 showed little change in either basal or induced levels of cdr1A, but showed high induction of MDR1, although knockout of this gene appeared to have no effect on azole susceptibility in susceptible isolates (Table 2 ). Our data show that cdr1B inactivation primarily affects the itraconazole MIC. As the other transporters studied in this paper appear not to be involved, it is likely that either non-transportermediated mechanisms of resistance or other transporters mediate voriconazole and posaconazole resistance in these strains. One isolate, F18454, showed increased expression of cdr1B, but an MIC of itraconazole of 0.5 mg/L. This suggests that other mechanisms may be required for full itraconazole resistance. Additionally, it can be seen from Figure 4 that expression patterns of cdr1B do not completely correlate with patterns of azole resistance. This highlights the probable existence of non-cyp51A multifactorial resistance mechanisms in these isolates.
Disruption of candidate transporter genes in an azolesusceptible strain resulted in few changes in azole susceptibility. Only the cdr1B knockout led to a 4-fold reduction in the MICs of all azoles tested in a clinical azole-susceptible isolate (Table 2) . cdr1B is slightly up-regulated in response to azole in our experiments and was also observed to be up-regulated (as abcC) by da Silva Ferreira et al. 36 When cdr1B and the highly induced MFS56 gene were disrupted in a non-cyp51A-mediated azole-resistant isolate, F20063, which displayed high overinduction of MFS56 and 6.2-fold over-induction of cdr1B, only the cdr1B knockout affected azole susceptibility. Notably, this knockout only affected susceptibility to itraconazole; the MIC decreased 4-fold from .8 to 2 mg/L. A number of possible explanations for this observation can be made. Firstly, it may be that cdr1B is largely responsible for itraconazole resistance in this strain, although knockouts do not return to wild-type levels of drug susceptibility. Additionally, the MIC of voriconazole is unchanged, whereas in wild-type cdr1B knockouts the MIC of voriconazole shows 4-fold greater susceptibility. Surprisingly, the MFS56 knockout in F20063 does not increase susceptibility to any tested azole in this strain, given the very high level of induction by azoles. In this case the residual MIC of itraconazole of 2 mg/L for the cdr1B knockouts strongly suggests the presence of other mechanisms that may also be responsible for resistance Fraczek et al.
to voriconazole and posaconazole. One limitation of these experiments is that induction profiles were only determined using itraconazole. Hence it is possible that different profiles could occur when isolates were treated with posaconazole or voriconazole and that such profiles could explain the observed differences in azole susceptibility. One possible scenario that could underpin the development of resistance in A. fumigatus is intermediate resistance mediated by transient up-regulation of a transporter such as cdr1B or MFS56, allowing fungal survival until stable resistance can arise, e.g. through mutation in the cyp51A gene. This has not occurred in the non-cyp51A resistant strains in this study. Resistance in these isolates is at the highest MIC measurable and is stable through many generations. The patients from whom these strains were isolated did not receive any unusual type, dose or duration of azole treatment and there appears to be no relationship between treatment duration and multi-azole resistance.
The qualitative similarity between the non-cyp51A strains and Candida azole resistance is clear: similar classes of transporter gene are up-regulated in both cases. cdr1B is an orthologue of CDR1. Orthologues of other C. albicans resistance-related transporters, such as CDR2, CDR4 and MDR1, do not play a discernible role in azole resistance in these isolates. Most azole resistance in C. albicans is attributed to transporter-mediated mechanisms, whereas in Aspergillus target site mutations have been more frequently documented. The reasons behind the shift away from target site mutation in azole-resistant isolates from Manchester is unknown, but the change is alarming in that it has the potential to confound recent molecular diagnostic tests using detection of mutations in the cyp51A gene to detect azole resistance.
The lack of correlation of transcriptional response between the azole-resistant strains and azole-susceptible 'wild-type' strains in this study implies that the use of azole-susceptible strains to gain insight into resistance mechanisms may not be a productive route to understanding of azole resistance in A. fumigatus, although in vivo investigations or experiments using different inductive media might increase the utility of such systems. As overexpression appears to be a route to resistance in A. fumigatus, a transcriptome-based approach might be a useful means of clarifying resistance mechanisms, although our results demonstrate that overexpression of a gene does not necessarily correlate with functional significance. 
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